Taking our lessons from the immune system, we develop highly selective therapeutics.

Expanding the range of immunotherapy options has been challenging for a number of reasons, including on-target/off-tumor activity, an immunosuppressive tumor microenvironment, and the cost and time constraints of personalized treatment.

TMAb™ Platform

Disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors

HQ: 451 D St, Unit 710 , Boston, MA 02210

MD: 1405 Research Blvd, Suite 125,
Rockville, MD 20850